Losartan — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Chronic Kidney Disease

• Amlodipine
• Atorvastatin
• Furosemide
• Lisinopril

Also listed for Heart Failure

• Carvedilol
• Digoxin
• Metoprolol
• Spironolactone

Other medications in Heart & Cardiovascular

• Lovastatin
• Macitentan
• Metolazone
• Metoprolol Succinate
• Milrinone
• Moexipril
• Nadolol
• Nebivolol

What Losartan is approved for (FDA label)

Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.

Source: Read the full FDA label on DailyMed. Label effective date: July 16, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Losartan (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue losartan potassium tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. [see Warnings and Precautions (5.1) ]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue losartan potassium tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: 9501dfaa-c8cf-46d6-8bec-936c4fd8fe03. Label effective date: July 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Losartan (FDA label)

• Losartan potassium tablets, 25 mg are white to off white, film coated, oval shaped tablets debossed with "I16" on one side and plain on other side. • Losartan potassium tablets, 50 mg are white to off white, film coated, oval shaped scored tablets debossed with "I" and "17" on either side of the score line on one side and plain on other side. • Losartan potassium tablets, 100 mg, are white to off white, film coated, oval shaped tablets debossed with "I18" on one side and plain on other side. Tablets: 25 mg; 50 mg; and 100 mg. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 9501dfaa-c8cf-46d6-8bec-936c4fd8fe03. Label effective date: July 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Losartan (FDA label)

Most common adverse reactions (incidence ≥2% and greater than placebo) are: dizziness, upper respiratory infection, nasal congestion, and back pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Granules Pharmaceuticals Inc at 1-877-770-3183 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Hypertension Losartan potassium tablets have been evaluated for safety in more than 3300 adult patients treated for essential hypertension and 4058 patients/subjects overall.

Source: FDA prescribing information (DailyMed). Set ID: 9501dfaa-c8cf-46d6-8bec-936c4fd8fe03. Label effective date: July 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Losartan (FDA label)

Losartan potassium tablets, are contraindicated: • In patients who are hypersensitive to any component of this product. • For coadministration with aliskiren in patients with diabetes. • Hypersensitivity to any component. ( 4 ) • Coadministration with aliskiren in patients with diabetes. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 9501dfaa-c8cf-46d6-8bec-936c4fd8fe03. Label effective date: July 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Losartan (FDA label)

• Hypotension: Correct volume or salt depletion prior to administration of losartan potassium tablets. ( 5.2 ) • Monitor renal function and potassium in susceptible patients. ( 5.3 , 5.4 ) 5.1 Fetal Toxicity Losartan potassium tablets can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.

Source: FDA prescribing information (DailyMed). Set ID: 9501dfaa-c8cf-46d6-8bec-936c4fd8fe03. Label effective date: July 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Losartan (FDA label)

• Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7.1 ) • Lithium: Risk of lithium toxicity. ( 7.2 ) • NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7.3 ) • Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7.4 ) 7.1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7.2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists.

Source: FDA prescribing information (DailyMed). Set ID: 9501dfaa-c8cf-46d6-8bec-936c4fd8fe03. Label effective date: July 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.